Drug Profile
AIC 476
Alternative Names: AIC476Latest Information Update: 28 Feb 2019
Price :
$50
*
At a glance
- Originator Bayer
- Class Antivirals
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cytomegalovirus infections
Most Recent Events
- 28 Feb 2019 No recent reports of development identified for phase-I development in Cytomegalovirus infections in Germany
- 23 Jan 2016 Phase-I clinical trials in Cytomegalovirus infections in Germany (unspecified route) before January 2016 (AiCuris pipeline; January 2016)